India to review COVID-19 vaccines after blood clot warning — report | Inquirer News

India to review COVID-19 vaccines after blood clot warning — report

/ 04:03 PM April 09, 2021

A nurse displays a vial of COVISHIELD, the AstraZeneca COVID-19 vaccine manufactured by Serum Institute of India, in Mumbai

FILE PHOTO: A nurse displays a vial of COVISHIELD, the AstraZeneca COVID-19 vaccine manufactured by Serum Institute of India, at a medical center in Mumbai, India, January 16, 2021. REUTERS/Francis Mascarenhas/File Photo

A government panel of experts is investigating for any domestic cases of blood clotting, even mild ones, as a side effect of the two COVID-19 vaccines being administered in India, financial daily Mint reported on Friday, citing two people aware of the development.

India is currently administering AstraZeneca’s COVID-19 vaccine, which is manufactured by the Serum Institute and branded Covishield, and a shot developed by Bharat Biotech called COVAXIN.

Article continues after this advertisement

The review comes after Europe’s drug regulator said on Wednesday it found a possible link between AstraZeneca’s vaccine and rare blood clotting issues in adults who had received the shot, although it added the vaccine’s advantages still outweighed the risks.

FEATURED STORIES

India is banking on vaccinations to help contain a record surge in cases in its second wave. The country reported a massive 126,789 new COVID-19 cases on Thursday.

“We are looking at side-effects of blood clots that have been seen in people who received Covishield and Covaxin, even if it was a mild case,” a source told Mint, who added that a report on it was likely to be ready by next week.

Article continues after this advertisement

Following Europe’s announcement, several countries have announced restrictions on the use of the AstraZeneca vaccine in younger people.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: AstraZeneca, India

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.